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Abstract Inflammation and oxidative stress are thought
to be involved in, or associated with, the development of
obesity, dyslipidemia, hepatic steatosis, and insulin resis-
tance. This work was designed to determine the evolution
of inflammation and oxidative stress during onset and pro-
gression of hepatic steatosis and glucose intolerance.
Seventy-five male Wistar rats were divided to control and
high-fat high-fructose (HFHFr) groups. A subgroup of each
group was sacrificed at 4, 8, 12, 16, and 20 weeks. HFHFr-
fed rats exhibited overweight, glucose intolerance, and
hepatic steatosis with increased contents of hepatic diacyl-
glycerols and ceramides. The HFHFr diet increased hepatic
interleukin 6 (IL-6) protein and adipose tissue CCL5 gene
expression and hepatic nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase activity but not mitochondrial
reactive oxygen species (ROS) production. The HFHFr diet
decreased plasma and liver levels of isoprostanoid metabo-
lites as well as plasma thiobarbituric acid-reactive sub-
stance (TBARS) levels. Hepatic glutathione content was
decreased with a moderate decrease in superoxide dismu-
tase (SOD) and glutathione peroxidase (GPx) with the
HFHFr diet. Overall, HFHFr diet led to hepatic lipid accu-
mulation and glucose intolerance, which were accompanied
by only moderate inflammation and oxidative stress. Most of
these changes occurred at the same time and as early as 8 or
12 weeks of diet treatment. This implies that oxidative stress
may be the result, not the cause, of these metabolic alter-
ations, and suggests that marked hepatic oxidative stress
should probably occur at the end of the steatotic stage to
result in frank insulin resistance and steatohepatitis. These
findings need to be further evaluated in other animal species
as well as in human studies.
Keywords Glucose intolerance  Hepatic steatosis  High-
fat diet  Inflammation  Isoprostanoids  Lipids  Metabolic
syndrome  Obesity  Oxidative stress  Rat
Lipids (2019).
Abbreviations
ADP adenine diphosphate
AGE advanced glycation end products
ALAT alanine aminotransferase
AUC area under the curve
* Charles Coudray
charles.coudray@inra.fr
1 DMEM (Dynamique Musculaire & Métabolisme) INRA,
University of Montpellier, 2 Place Viala, 34060 Montpellier,
France
2 Institut des Biomolécules Max Mousseron, IBMM, University of
Montpellier, CNRS, ENSCM, 15 Avenue Charles Flahault,
34090 Montpellier, France
3 PhyMedExp, University of Montpellier, INSERM, CNRS, 371
avenue Doyen Gaston Giraud, 34295 Montpellier, France
4 Physiology Department, Medical University of Bialystok, Jana
Kilinskiego 1, 15-089 Bialystok, Poland
5 Epidemiology and Metabolic Disorders Department, Medical
University of Bialystok, Jana Kilinskiego 1, 15-089 Bialystok,
Poland
6 UMR U1060, INSERM, Faculté de médecine Lyon-Sud, 165
Chemin du Grand Revoyet, 69921 Oullins, France
7 Aix Marseille University, INSERM, INRA, C2VN, 27 boulevard
Jean Moulin 13385, Marseille, France
Ccl5 chemokine (C-C motif) ligand 5
DAG diacylglycerols
FFA unesterified fatty acids
G glutamate
GPx glutathione peroxidase
GSH glutathione
GssG oxidized glutathione
HFHFr high-fat high-fructose groups
IL-6 interleukin 6
M Malate
Mcp-
1 (CCl2)
monocyte chemoattractant protein 1
MetS metabolic syndrome
MUFA monounsaturated fatty acids
NAFLD nonalcoholic fatty liver diseases
OGTT oral glucose tolerance test
PUFA polyunsaturated fatty acids
qPCR quantitative polymerase chain reaction
RLU relative luminescence unit
ROS reactive oxygen species
RT-qPCR Real-time quantitative polymerase chain
reaction
S Succinate
SFA saturated fatty acids
SOD superoxide dismutase
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Ultra-high performance liquid chromatogra-
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Introduction
Increased consumption of energy-dense foods containing
high amounts of animal fats, saturated fatty acids, and fruc-
tose is thought to be the major contributor to the current
epidemic overweight and obesity worldwide (Dandona
et al., 2005; Zivkovic et al., 2007). Abdominal obesity,
dyslipidemia, and nonalcoholic fatty liver diseases
(NAFLD) are among the major metabolic syndrome
(MetS) features, which include also insulin resistance and
hypertension (Johnson et al., 2013). When lipid intake
exceeds energy expenditure demand, excess lipid is first
accumulated in the adipose tissue, which plays a buffer role
in the first high-energy exposure. However, when this res-
ervoir is exceeded, the excess lipid can attain other impor-
tant metabolic tissues, in particular liver and muscle
(ectopic lipids) leading to hepatic steatosis, glucose intoler-
ance, and type-II diabetes development. Moreover, most
studies agree that it is not the lipid accumulation that causes
glucose intolerance, but rather lipid intermediates such as
fatty acyl-CoA, diacylglycerols (DAG), and ceramides and
particularly the localization, the composition, and the turn-
over of these intermediates that play an important role in
the development of hepatic steatosis, glucose intolerance,
and type-II diabetes (Perry et al., 2014; Petersen and Shul-
man, 2017).
The first stage of NAFLD is the liver lipid accumulation.
This later may come from the lipid diet, de novo lipogene-
sis or adipose lipid release. (Kawano and Cohen, 2013).
Low-grade inflammation and oxidative stress are thought
to be involved in the initiation of this metabolic disorder
(Anderson et al., 2009; Ando and Fujita, 2009). Together
with other cellular factors, high inflammation, free radicals,
and marked oxidative stress are generally involved in the
progression of hepatic steatosis to steatohepatitis, fibrosis,
cirrhosis, and hepatocarcinoma (Ucar et al., 2013). Indeed,
high reactive oxygen species (ROS) generation may con-
tribute to tissue damage and dysfunction in different ways:
(1) it may directly dysregulate redox-sensitive signaling
pathways, and (2) may cause oxidative damage to biologi-
cal structures. The mitochondrial electron transport chain is
known to be one of the major producers of superoxide
anions, which are precursors to other ROS such as hydro-
gen peroxide and hydroxyl radicals. The other important
physiological system of cellular ROS production is the
NADPH oxidase (Valko et al., 2007).
Mitochondria play a central role in cellular energy
metabolism by transforming the energy stored in nutrients
into adenosine triphosphate through the reduction of oxy-
gen into water through the complexes of the mitochondrial
respiratory chain. However, a small proportion of electrons
may react directly with O2 at the level of complexes I and
III of the respiratory chain, with production of ROS more
or less important.
Emerging evidence implicates mitochondrial dysfunc-
tion, with a concomitant increase in ROS production, con-
tributing to obesity-induced fatty liver disease (Mantena
et al., 2008). The NADPH oxidase complex is another
important source of cellular ROS production that generates
ROS in response to a wide range of nutritional and non-
nutritional stimuli (Bedard and Krause, 2007). Although
NADPH oxidase-ROS production is generally under con-
trol and involved in specific signaling pathways, high or
uncontrolled activation of NADPH oxidase may lead to
ROS overproduction and then to oxidative stress under cer-
tain conditions (Paik and Brenner, 2011).
Inflammation and oxidative stress are each indepen-
dently involved in the development and progression of
many metabolic syndrome features. The crucial roles of
inflammation and oxidative stress in the development of
hepatic diseases have been emphasized for decades, where
hepatic inflammation and oxidative stress are sustained and
participated in this pathological progressive process
into 10 groups corresponding to different sacrifice-time
points (five groups fed the control diet and five other
groups fed the HFHFr diet). This randomization was based
on the initial rat body weight. Fasted rats (seven control rats
and eight HFHFr rats) were sacrificed after 4, 8, 12, 16, or
20 weeks on their respective diets.
The control diet contains 4% lipids as soybean oil, and
the HFHFr diet contains 35% lipids (1% soybean oil +8.5%
lard +17% palm oil +8.5% cocoa butter) and 25% fructose
(Table 1). The high-fat diet was supplemented with 1%
soybean oil to maintain an adequate intake of linoleic acid
and to avoid growth alterations resulting from linoleic acid
deficiency. Refined palm oil (VAMOLINE) was purchased
from Vandemoortele Lipids and Dough Division, Izegem,
Belgium. The lipid fraction of the control diet was com-
posed of 17.4% saturated fatty acids (SFA), 28.1% mono-
unsaturated fatty acids (MUFA), and 54.5%
polyunsaturated fatty acids (PUFA), and that of the HFHFr
diet was composed of 44.2% SFA, 43.2% MUFA, and
12.6% PUFA (Table 2). In addition to the high level of
lipids in the HFHFr diet, the percent of both SFA and
MUFA was greatly increased whereas that of PUFA was
substantially decreased compared to the control diet. Rats
Table 1 Diet compositiona (g/kg)
Ingredient Control HFHFr
Casein 150 180
Cornstarch 456.8 75.1
Maltodextrine 155 25
Sucrose 100 0
Fructose 0 250
Soybean oil 40 10
Lard 0 85
Refined palm oil 0 170
Cocoa butter 0 85
Cellulose 50 60
Mineral mix (AIN-93 M)b 35 42
Vitamin mix (AIN-93 M)c 10 12
L-Cystine 1.8 2.2
Choline chloride 1.4 1.7
Total 1000 1000
Refined palm oil (VAMOLINE) was purchased from Vandemoortele
Lipids and Dough Division Prins Albertlaan 12, 8870 Izegem, Bel-
gium. HFHFr, high-fat high-fructose.
aDiet composition was based on the AIN-93 M diet formulation.
bMineral mix AIN 1993 ensures the following mineral levels in the
diets (mg/kg): Na, 1020; K, 3600; P, 4000; Ca, 5000; Mg, 500; Zn,
30; Fe, 35; Cu, 6; Mn, 54; Se,0.1; I, 0.2; and Cr, 2.
cVitamin mix AIN 1993 ensures the following mineral levels in the
diets (mg/kg): thiamine, 6; riboflavine, 6; pyridoxine, 7; nicotinic
acid, 30; calcium pantothenate, 16; folic acid, 2; D-biotin: 0.2; and
(μg/kg) cyanocobalamine (vitamin B12), 10; vitamin K, 50; and
(IU/kg) vitamin A, 4000; vitamin E, 50; and vitamin D, 1000.
(Fernandez-Sanchez et al., 2011). Indeed, there is growing 
evidence that inflammation and oxidative stress are closely 
related, creating a vicious circle that can, for example, 
aggravate nonalcoholic fatty liver disease into nonalcoholic 
steatohepatitis and cirrhosis (Li et al., 2016). Low-grade 
inflammation is a reported characteristic of the obese state, 
and adipose tissue releases many inflammatory mediators. 
These include highly active molecules like leptin, resistin, 
and adiponectin as well as some more classical cytokines. 
Most likely, proinflammatory cytokines such as tumor 
necrosis factor-α (TNF-α) and interleukin1 and 6 (IL-1 and
-6) are released by the inflammatory cell infiltrates includ-
ing monocytes/macrophages, neutrophils, B lymphocytes, 
T lymphocytes, and others (Gerner et al., 2013). Obese 
individuals have been reported to have circulating levels of 
many inflammatory markers higher than lean individuals, 
and these may play a major role in insulin resistance and 
other metabolic disorders (Tordjman et al., 2008).
Therefore, it is generally accepted that the development 
of metabolic syndrome features, in particular obesity, 
hepatic steatosis, and insulin resistance, is initiated by, or 
accompanied by inflammation and oxidative stress in liver 
and adipose tissue (Renaud et al., 2014). Undeniably, one 
crucial question that comes up is whether inflammation and 
oxidative stress contribute to, or are simply a consequence 
of, the two main features of the metabolic syndrome-that is 
installation and development of fatty liver and glucose 
intolerance. The present work was designed to determine 
the evolution of both inflammation and oxidative stress 
markers during obesity, hepatic steatosis, and glucose intol-
erance development in a high-fat high-fructose group 
(HFHFr) diet-fed rats. The novelty of this work is the 
investigation of a wide range of measured outcomes of oxi-
dative stress, in particular the isoprostanoid metabolites, in 
a large longitudinal study with several end-points from 4 to 
20 weeks diet treatment with a control group at each time 
point. This approach allows an integrated overview of the 
physiological time-course evolution of both inflammation 
and oxidative stress and their impact on the major MetS 
features such as obesity, hepatic steatosis, and glucose 
intolerance development.
Materials and Methods
Animals and Diets
Seventy five 4-week-old male Wistar rats (~100 g, Charles 
River, L’Arbresle, France) were housed (2 per cage) under 
conditions of constant temperature (20–22 C), humidity 
(45–50%), and a standard dark cycle (20.00–08.00 h). At 
the beginning of the study, the rats were block randomized
were given free access to food and tap water throughout the
study. The rat body weight was determined weekly and
food consumption was determined every 2 or 3 days. Our
institution guidelines for the care and use of laboratory ani-
mals were observed and all experimental procedures were
approved by the local ethical committee in Montpellier,
France (Reference CEEA-LR-12002).
Animal Sacrifice and Metabolic Biochemical Analyses
At 4, 8, 12, 16, and 20 weeks of diet, eight to 10 h-fasted
rats (23 h:00–08 h:00) were anesthetized with pentobarbi-
tal (40 mg/kg b.w.) and blood was drawn from the abdomi-
nal artery with a heparinized syringe, to avoid blood
coagulation during sampling, and transferred to dry and
heparinized tubes. 100 μL of heparinized blood were mixed
with 900 μL of metaphosphoric acid 6% and centrifuged
and the supernatant was recovered for blood glutathione
(GSH) and oxidized glutathione (GssG) measurement.
Blood tubes were centrifuged at 1000g for 10 min at 4 C,
plasma or serum was collected and stored at −80 C until
analysis. Liver and visceral fats (retroperitoneal and epidid-
ymal depots) were removed, rinsed with 0.9% NaCl,
weighed and frozen in N2, and kept at −80 C until ana-
lyses, except a part of liver that was used for the extempo-
raneous isolation of liver fresh mitochondria.
Liver Histological Analysis
For microscopic studies, liver samples were fixed in 10%
neutral buffered formalin and embedded in paraffin. Serial
tissue sections (5 μm) were processed. Hepatic steatosis
was evaluated by histological examination after hematoxy-
lin/eosin staining. Liver sections were observed under a
Nikon Eclipse TE300 microscope. Images were acquired
using the ToupView software driving a ToupCam CCD
camera on at least 10 fields (X200) per section. The vesicu-
lar (lipids) area was graded from 1 to 4, where 1 corre-
sponds to 0–25% of the tissue area presenting fatty
vacuoles, 2% to 25–50%, 3% to 50–75%, and 4% to
75–100%. For each group, liver samples from six to eight
rats were prepared, stained, and examined.
Hepatic DAG and Ceramide Contents
The liver ceramide content was measured using a
UHPLC/MS/MS approach, as previously described with a
minor modification (Blachnio-Zabielska et al., 2012).
Briefly, the liver samples (20 mg) were pulverized and
homogenized in a solution composed of 0.25 M sucrose,
25 mM KCl, 50 mM Tris, and 0.5 mM éthylènediamineté-
traacétique (EDTA), pH 7.4. Immediately afterward, the
internal standards (d17:1/8:0, d17:1/18:0, d17:1/18:1(9Z),
Table 2 Fatty acid composition of the experimental dietsa (mg/g diet)
Fatty acids Control diet (%) Control diet (mg/g) HFHFr diet (%) HFHFr diet (mg/g)
14:0 0.430.05 0.170.170.02 1.090.16 3.823.820.56
16:0 11.70.1 4.684.680.04 30.40.4 106.106.41.4
16:1n-7 0.160.01 0.060.060.00 0.910.03 3.193.190.11
18:0 4.430.05 1.771.770.02 12.10.2 42.342.350.70
18:1 n-9 26.10.2 10.410.440.08 40.10.4 140.140.351.4
18:1 n-7 1.530.06 0.610.610.02 1.370.01 4.794.790.04
18:2 n-6 48.80.3 19.519.520.12 11.50.1 40.240.250.35
18:3 n-3 5.580.05 2.232.230.02 0.710.02 2.492.490.07
20:x 0.380.01 0.150.150.00 0.490.02 1.721.720.07
22:x 0.470.01 0.190.190.00 0.130.01 0.460.460.03
SFAb 17.40.1
6.966.960.04
44.20.4
154.154.71.4
MUFAb 28.10.2 11.211.240.08 43.20.2 151.151.20.7
PUFAb 54.50.4 21.821.80.16 12.60.2 44.144.10.7
unsaturated FA 82.60.1 33.033.040.04 55.80.3 195.195.31.05
n-6 48.80.3 19.519.520.12 11.60.1 40.640.60.35
n-3 5.670.10 2.272.270.04 1.000.05 3.53.50.18
n-6/n-3 8.650.12 3.463.460.05 11.70.1 40.940.90.35
PUFA/SFAb 3.120.04 1.251.250.02 0.280.01 0.980.980.04
HFHFr, high-fat high-fructose.
aValues are based on identifiable peaks.
bMUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; and SFA: saturated fatty acids.
Mitochondrial ROS production was measured on fresh
mitochondria as previously described (Barja, 2002). Briefly,
reaction mixtures (2 mL), containing MIRO5 buffer, dihy-
drodichlorofluorescein (10 μM), and peroxidase (2 IU/mL),
were incubated with 50 μg of mitochondrial proteins with or
without substrates (malate/glutamate/succinate
(S) 2.5/5/5 mM, respectively) and with or without adenine
diphosphate (ADP) (0.5 mM). Fluorescence was measured
60 min after reaction initiation at λEx =490 and λEx =525 nm
excitation and emission, respectively.
NADPH oxidase dependent-superoxide anion production
was determined on rat liver as previously described
(Feillet-Coudray et al., 2009). Briefly, liver homogenates
were incubated at 37 C for 30 min in the presence or
absence of diphenyleneiodonium (DPI), a NADPH oxidase
inhibitor. Lucigenin-enhanced chemiluminescence was
assessed to determine O2
– generation after adding NADPH,
the substrate for NADPH oxidase. The chemiluminescence
signals were measured using a microplate luminometer
LB96V (Berthold) for 30 min. The results were expressed
as the relative luminescence unit (RLU) and were corrected
for protein concentration. In addition, the hepatic protein
expression of two major NADPH oxidase subunits, p22phox
and p47phox, was also determined. See the WB procedure
section for details.
Plasma and Liver Oxidative Stress Parameters
Isoprostanoid metabolites measurement: To measure oxida-
tive damage to lipids, the levels of isoprostanoids in plasma
and liver were measured based on the micro-LC–MS/MS
technique (Dupuy et al., 2016). Briefly, after lipid extrac-
tion with the Folch mixture, the extracts were mixed with a
cocktail of internal standards, and an alkaline hydrolysis
was performed. The metabolites were concentrated thanks
to a solid phase extraction step conduced on weak-anion
exchange materials. The metabolites were then analyzed
using micro-LC–MS/MS. Mass spectrometry analysis was
performed in an AB Sciex QTRAP5500 (Sciex Applied
Biosystems). The ionization source was electrospray in
negative mode. Detection of the fragmentation ion products
from each deprotonated molecule was performed in the
multiple reaction monitoring mode. Quantification of
metabolites was done, using MultiQuant 3.0 software, by
measuring the ratio of area under the specific metabolite
peak/area under the internal standard peak and compared to
the ratio of area under the metabolite calibration peak/area
under the internal standard peak.
Liver protein carbonylation: The Oxyblot-Oxidized Pro-
tein Detection Kit was purchased from Chemicon
(Hampshire, UK). The carbonyl groups in the protein side
chains are derivatized to 2,4-dinitrophenol (DNP)-
hydrazone by reaction with 2,4-dinitrophenylhydrazine,
d17:1/20:0, d17:1/24:0, and d17:1/24:1(15Z) (Avanti Polar 
Lipids, Alabaster, AL, USA) were added. The mixture was 
vortexed, sonicated, and centrifuged. The supernatant was 
transferred to a new tube and pellet was re-extracted. 
Supernatants were combined and evaporated under nitro-
gen. The dried sample was reconstituted in 100 μL of  LC  
Solvent A for LC/MS/MS analysis. Quantitative measure-
ment was made using a triple quadrupole mass spectrome-
ter (Agilent 6460, Santa Clara, CA, USA) in positive mode 
using multiple reaction monitoring. All ceramides were 
quantified against standard concentration curves.
The liver DAG content was measured using a 
UHPLC/MS/MS approach, as previously described 
(Blachnio-Zabielska et al., 2013). Briefly, DAG were 
extracted together with ceramides. A known amount of 
internal standard mix (Deuterated DAG Mixture I and Mix-
ture II – Avanti Polar Lipids) was added to each sample. 
Next, samples were extracted as described above. The fol-
lowing DAG species were quantified: 18:1/18:2, 16:0/18:2, 
16:0/16:0, 16:0/18:1, 18:0/20:0, 18:0/18:1, 18:1/18:1, 18:0/ 
18:2, and 16:0/18:0 using UHPLC/MS/MS. The DAG con-
tent was analyzed by means of a triple quadrupole mass 
spectrometer using a positive ion electrospray ionization 
source with multiple reaction monitoring against the stan-
dard concentration curves.
Plasma, Liver, and Adipose Tissue Inflammatory 
Markers
The plasma levels of TNF-α, IL-6, and MCP-1 were mea-
sured using cytokine-specific enzyme-linked immunosor-
bent assay (ELISA) kits (Invitrogen, Life Technologies, 
Cergy Pontoise, France). Liver protein abundance of TNF-
α and IL-6 was also determined. See the Western blot 
(WB) procedure section. In addition, the gene expression
of four major inflammatory actors (TNF-α, IL-6, MCP-1, 
and CCL5) was also determined in the retroperitoneal adi-
pose tissue. See the quantitative polymerase chain reaction 
(qPCR) procedure section for details.
Hepatic Mitochondrial and NADPH Oxidase ROS 
Production
Liver mitochondria were extemporaneously isolated using 
the differential centrifugation technique (Aoun et al., 
2011). The final mitochondrial pellet was suspended in 
1 mL mitochondrial respiration O5 (MIRO5) buffer 
(Sucrose 110 mM, Hepes 20 mM, KH2PO4 10 mM, Tau-
rine 20 mM, K-Lactobionate 60 mM, MgCl2 3 mM ethyl-
ene glycol-bis(2-aminoethylether)-N N N0N0-tetraacetic 
acid (EGTA) 0.5 mM, bovine serum albumin (BSA) 1 g/L, 
pH 7.1). Protein content was determined using bovine 
serum albumin as standard (Bradford, 1976).
following the manufacturer’s instructions (Bravard et al.,
2011). Briefly, after the derivatization of the protein sam-
ple, one-dimensional electrophoresis was carried out on a
10% sodium dodecyl sulfate polyacrylamide (SDS-PAGE)
gel. Proteins were transferred to polyvinylidene difluoride
membranes. After incubation with the anti-DNP antibody,
the blot was developed using a chemiluminescence detec-
tion system. After transfers, the gels were stained with Coo-
massie Brilliant Blue to verify protein loading. These gels
were scanned, and the intensity of each line allowed the
normalization of the densitometry analysis of carbonylated
proteins.
Long-established oxidative stress parameters: in addition
to the isoprostanoid metabolites and protein carbonylation
measurements, several long-established parameters of
oxidative stress have also been evaluated. Thiobarbituric
acid-reactive substances (TBARS), representing lipid per-
oxidation, were measured in plasma and liver homogenates
by mixing the biological samples with thiobarbituric acid at
100 C and monitoring the pink color absorbance at
532 nm (Sunderman et al., 1985; Yagi, 1984). Protein oxi-
dation was assessed in plasma and liver supernatants by
measuring the sulfhydryl groups using the Ellman reagent
and monitoring the yellow color absorbance at 412 nm
(Jocelyn, 1987). Plasma levels of advanced glycation end
products (AGE) were evaluated monitoring the optical den-
sity at 430 nm after simple dilution in PBS-acetic acid
buffer (Witko-Sarsat et al., 1998).
Total glutathione (GSH + GssG) and oxidized GSH
were measured in blood and liver homogenates deprotei-
nized with metaphosphoric acid. The blood and liver super-
natants were mixed with the Ellman reagent and
absorbance was monitored at 412 nm (Griffith, 1980).
Total superoxide dismutase (SOD) was measured in plasma
and liver supernatants by monitoring the inhibition of the
auto-oxidation of pyrogall at 320 nm (Marklund, 1976).
Catalase activity was measured in liver supernatants using
H2O2 as a substrate and absorbance was monitored at
240 nm (Beers and Sizer, 1952). Glutathione peroxidase
(GPx) was measured in plasma and liver supernatants using
ter-butylhydroperoxide, GSH, GRx, and NADPH as sub-
strates and monitoring the oxidation of NADPH at 340 nm
(Flohe and Gunzler, 1984).
Liver Protein Isolation and Western Blotting
The hepatic abundance of major proteins involving inflam-
mation and NADPH oxidase regulation was determined.
Liver samples were homogenized using an Ultra Turax
homogenizer in an ice cold lysis buffer: 20 mM Tris pH 8,
50 mM DL-Dithiothreitol, 150 mM NaCl, 2 mM EDTA,
1% Triton X100, 0.1% sodium dodecyl sulfate (SDS),
1 mM phenylmethane sulfonyl fluoride (PMSF), 1 mM
orthovanadate, and 1% of antiprotease cocktail. Proteins
were separated with 10% or 8% SDS-PAGE and then trans-
ferred to a nitrocellulose membrane. Membranes were
blocked in 5% nonfat milk for 1 h at room temperature.
Membranes were incubated overnight at 4 C with a pri-
mary antibody against TNF-α (Abcam ab66579), IL-6
(Abcam ab25107), and subunits of NADPH oxidase
p22phox (Abcam ab75941) and p47phox (Sigma-Aldrich
SAB4502810) in blocking buffer. After washes in
TBS/Tween buffer, membranes were incubated for 1 h with
the horseradish peroxidase-labeled antibody. The antirabbit
IgG, HRP-linked Antibody (Cell Signaling 7074) was used
as a secondary antibody. After further washes, blots were
treated with enhanced chemiluminescence detection
reagents. β-actin (Santa Cruz sc-81,178) was used as load-
ing references, and blot intensities were measured using the
Image Labs software 5.2.1 (Bio-Rad Laboratories. France).
Adipose Tissue RT-qPCR Analysis
Real-time quantitative polymerase chain reaction (RT-
qPCR) was applied to measure key inflammation gens
mRNA expression in the adipose tissue. Adipose tissue
RNA was extracted with the Trizol reagent (Invitrogen Life
Technologies, Cergy Pontoise, France). The reverse tran-
scription reaction was performed with 1 μg total RNA.
Complementary deoxyribonucleic acid (cDNA) was syn-
thesized with the use of moloney murine leukemia virus
reverse transcriptase for first strand cDNA synthesis and
random primers. The mRNA expressions of target genes
(TNF-α, IL-6, MCP-1, and CCL5) were determined by RT-
qPCR. RT-qPCR analysis was performed using SYBR
Green Mastermix (Eurogentec, liege, Belgium) with a
Mx3005P Real-Time PCR System (Stratagene, La Jolla,
CA, USA). Results were normalized with the gene encod-
ing 18S. The primer sequences used for real-time RT-PCR
are given in Table 3. The mean expression levels and the
standard deviations of the housekeeping 18S rRNA gene
were as follows: 5.56  0.17; 5.81  0.2; 5.78  0.25;
5.84  0.42; and 5.75  0.06 for control groups (4, 8,
12, 16, and 20 weeks, respectively) and 5.44  0.18;
5.55  0.13; 5.49  0.15; 5.69  0.5, and 5.53  0.190 for
HFHFr groups (4, 8, 12, 16, and 20 weeks, respectively).
Statistical Analysis
Results were expressed as means  SD, n = 7–8 animals
per group per treatment duration. All the groups were tested
for the effects of diet type, treatment duration, and their
interaction by the two-way ANOVA test. When the effects
of diet or treatment duration were significant, the unpaired
Student’s t-test was used to analyze the effect of HFHFr
diet within each diet treatment duration point and the one-
the HFHFr diet-fed rats than in the control rats (Fig. 2a).
The high score of these lipid vesicles in the HFHFr diet-
fed rats confirmed hepatic steatosis in this rat model
(Fig. 2b). In addition, the plasma alanine aminotransferase
(ALAT) activity, a marker of liver damage indicative of
both cellular leakage and loss of liver cell membrane func-
tional integrity, was significantly increased with the
HFHFr diet compared to control diet (Fig. 2c).
Blood and Tissue Inflammation Status
The major cytokines TNF-α, IL-6 and the chemokines
MCP-1 and CCL5, involved in systemic inflammation,
were investigated in blood, liver, and/or adipose tissue. The
plasma levels of both TNF-α and IL-6 were increased
throughout the study in both rat groups. However, the
plasma levels of TNF-α, IL-6, and MCP-1 remained
unchanged between HFHFr and control groups (Table 4).
In the liver tissue, the protein abundance of TNF-α
remained unchanged whereas the protein abundance of IL-
6 was increased, with high variability (Table 4). In addi-
tion, the gene expression of two cytokines (Tnfa, Il6) and
two chemokines (Mcp1, Ccl5) was also investigated in the
adipose tissue. The expression of three genes out of four
was increased significantly (Tnfa, Mcp1, and Ccl5)
throughout the study in both rat groups. Nevertheless, only
the gene expression of Ccl5 was highly increased with the
HFHFr diets compared to the control diets (Table 4).
Mitochondrial and NADPH Oxidase ROS Production
Hepatic mitochondrial ROS production was evaluated on
extemporaneously isolated liver mitochondria alone or
challenged with substrates or with substrates plus ADP. As
shown in Fig. 3a, mitochondrial ROS production remained
substantially the same under the three experimental condi-
tions. Interestingly, the NADPH oxidase dependent-
superoxide anion production was highly increased with the
HFHFr diet compared to the control diet at the five
explored time points (Fig. 3b). Nevertheless, the investiga-
tion of the two major proteins of hepatic NADPH oxidase,
Table 3 Primer sequences for mRNA assays of inflammation genes for adipose tissue qPCR analyses
Gene Forward Sequence (50-30) Reverse Sequence (50-30)
Tnfa GCCCAACC CTCACACTC CCACTCCAGCTGCTCCTCT
Il6 CCCTTCAGGAAC AGCTATGAA ACAACATCAGTCCCAAGA AGG
Mcp1 AGCATCCACGTGCTGTCTC GATCATCTTGCCAGTGAATGAGT
Ccl5 CTCACCGTCATCCTCGTT G GAGTGGTGTCCGAGCCATA
House Keeping Gene
18S RRNA GTGGGCCTGCGGCTTAAT GCCAGAGTCTCGTTCGTTATC
Tnfa: Tumor necrosis factor-a; Il6: interleukine-6; Mcp1 (CCL2): Monocyte chemotactic protein-1; Ccl5: Chemokine (C-C motif) ligand 5; and
18S RRNA: 18S Ribosomal ribonucleic acid.
way ANOVA test was applied to analyze the effect of treat-
ment duration for each diet followed up by a Fisher’s Least 
Significant Difference test. The oral glucose tolerance test 
(OGTT) and the mitochondrial ROS production assessment 
were performed extemporaneously on 4, 8, 12, 16, and 
20 weeks, and the WB analysis was carried out time point 
by time point. Therefore, the statistical analysis of these 
later data was made only between HFHFr and control diets, 
inside of each treatment duration, by the unpaired Student’s
t-test. The limit of statistical significance was set at 
p < 0.05. HFHFr diet versus control diet: *p < 0.05, 
**p < 0.005, and ***p < 0.0005. Correlations were per-
formed with the Spearman method. Statistical analyses 
were performed using the StatView program (SAS Insti-
tute, Cary, NC, USA).
Results
Hepatic Lipid Accumulation and Histological Analysis
DAG and ceramide species are known as lipotoxic com-
pounds and may have impact on hepatic insulin resistance. 
The liver content of total DAG was increased significantly 
(+100%) under the HFHFr diet with a maximum on 16 weeks 
of diet intake compared to the control diet (Fig. 1a). Indeed, 
four DAG species were increased (16/18, 16/18:1, 18/18:1, 
and 18:1/18:1), whereas only one remained unchanged 
(16/16) and two were decreased (16/18:2 and 18:1/18:2)
(Table S1, Supporting information).
In addition, the liver content of total ceramides was mod-
erately but significantly increased under the HFHFr diet 
compared to the control diet (Fig. 1b). Indeed, five out of 
10 ceramide species remained unchanged (SPA, Sph, 18:1, 
24, and 24:1), whereas two were decreased (14 and 16) and 
three were increased (18, 20, and 22). Therefore, the overall 
increase in the liver total ceramide content is due largely to 
the high increase in one of the major ceramide species, 
namely, the 22 species (Table S2).
As expected, the liver histological analysis, using 
hematoxylin/eosin staining, showed more lipid vesicles in
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(Fig. 4b–d). The metabolite of the class D
(F3-neuroprostane) was not detectable. Consequently, the
plasma total isoprostanoid content was decreased signifi-
cantly under the HFHFr diet compared to the control diet
(Fig. 4f). Such a decrease was marked from the 12 weeks
of diet intake (Fig. 4f). The plasma individual isoprosta-
noid metabolites are shown in Table S3.
The liver isoprostanoid contents of the classes A, B, C,
and E were decreased significantly under the HFHFr diet
compared to the control diet (Fig. 5a, b, c, e). Only the
F3 t-neuroprostane metabolite was increased (class D,
Fig. 5d). Therefore, the liver total isoprostanoid content
was decreased significantly under the HFHFr diet com-
pared to the control diet. Such a decrease was observed on
12, 16, and 20 weeks of diet intake (Fig. 5f). The liver indi-
vidual isoprostanoid metabolites are shown in Table S4.
As the hepatic isoprostanoid content may depend on the
hepatic levels of their original fatty acids, we have also looked
at the ratio of liver isoprostanoid/original fatty acid of the iso-
prostanoid classes as well as at the ratio of total isoprostanoid/
total PUFA. Interestingly, the ratio of isoprostanoid/fatty acid
Table 4 Blood, liver, and adipose tissue inflammatory status
Parameter Diet 4 weeks 8 weeks 12 weeks 16 weeks 20 weeks p diet p time p interaction
Plasma
TNF-α (μg/L) Control 5.80.61 7.72.32 11.41.13 13.31.34 14.50.94
HFHFr 6.51.1a 8.11.4b 11.20.6c 13.21.7d 14.61.1e NS <0.0001 NS
IL-6 (μg/L) Control 11.95.91 19.17.71,2 24.71.92 34.68.63 45.68.84
HFHFr 14.65.6a 17.74.6a 24.62.2b 38.56.2c 48.59.1d NS <0.0001 NS
MCP-1 (ng/L) Control 9323 11234 8617 11833 11016
HFHFr 10319 9013 9615 10617 10716 NS NS NS
Liver
TNF-α, WB Control 10031 10047 10036 100035 10031
HFHFr 9830 9315 9742 8627 8619 NA NA NA
IL-6, WB Control 10068 10060 10057 10047 10094
HFHFr 287167* 351254* 408286* 265118** 320215* NA NA NA
Adipose tissue
Tnf-α, qPCR Control 1001201,2 77361 59391 115541,2 146362
HFHFr 8434a 7612a 7928a 12954b 15264b NS 0.0011 NS
Il-6, qPCR Control 10092 6262 18832 14984 212101
HFHFr 3734 8083 117144 136108 194296 NS 0.0827 NS
Mcp-1, qPCR Control 100501 102611 126791 1681011,2 2481602
HFHFr 8437a 13155a 13196ab 16481bc 216107c NS 0.0009 NS
Ccl5, qPCR Control 100361 73691 53401 101661 1261481
HFHFr 6633a 146115a 198111*a 323162**b 440273*b 0.0001 0.0038 0.0206
Results were expressed as means  SD, n = 6–8 animals per group per treatment duration. All the groups were tested for the effects of diet, treat-
ment duration, and their interaction using a two-way ANOVA. When the effects of diet or treatment duration were significant, the unpaired Stu-
dent’s t-test was used to analyze the effect of high-fat high-fructose (HFHFr) diet within each diet treatment duration point and the one-way
ANOVA test was applied to analyze the effect of treatment duration for each diet followed up by a Fisher’s Least Significant Difference test. The
limit of statistical significance was set at p < 0.05. HFHFr diet versus control diet: *p < 0.05, **p < 0.005. Values in the same row with different
superscript digits (1, 2, 3, and 4 for control groups) or with different superscript letters (a, b, c, d, and e for HFHFr groups) are significantly differ-
ent from each other (p < 0.05). NS: not significant; NA: non applicable. TNF-α: tumor necrosis factor-α; Il-6: interleukine 6; Mcp-1: monocyte
chemoattractant protein 1; and Ccl5: chemokine (C-C motif) ligand 5.
p22phox and p47phox, did not indicate any significant differ-
ence between HFHFr and control groups at any treatment 
duration (Fig. 3b).
Plasma and Liver Isoprostanoid Contents
This study consists of LC–MS profiling of 14 isoprostanoid 
metabolites in plasma and in liver. We have classified the 
measured isoprostanoid metabolites into six classes accord-
ing to their fatty acid origin: class A: radical metabolites of 
α-linolenic acid (18:3 n-3), class B: radical metabolites of 
arachidonic acid (20:4 n-6), class C: radical metabolites of 
all-cis-7,10,13,16-docosatetraenoic acid (adrenic acid)
(22:4 n-6), class D: radical metabolites of docosapentaenoic 
acidn-6 (22:5 n-6), class E: radical metabolites of docosa-
hexaenoic acid (22:6 n-3), and class F: enzymatic metabo-
lites of arachidonic acid (20:4 n-6).
If the plasma isoprostanoid content of class A and F 
remained unchanged (Fig. 4a, e), the plasma isoprostanoid 
contents of classes B, C, and E were decreased significantly 
under the HFHFr diet compared to the control diet
for the isoprostanoid classes C and E as well as for the ratio
total isoprostanoids/total PUFA remained lower with the
HFHFr diet than with the control diet (Table S5).
Long-Established Oxidative Stress Parameters
As for isoprostanoids, plasma TBARS levels were
decreased moderately but significantly under the HFHFr
diet compared to the control diet, in particular on 4, 12, and
16 weeks of diet (Fig. 6a). However, plasma AGE levels
were significantly increased with the HFHFr diet compared
to the control diet on 8 and 12 weeks of diet (Fig. 6b).
Plasma SH group levels were significantly decreased with
the HFHFr diet compared to the control diet (Fig. 6c),
whereas total GSH, GssG levels, and GssG/GSH ratio
remained unchanged throughout the study between the two
experimental diets (Fig. 6d). Finally, plasma antioxidant
enzymes SOD and GPx (Fig. 6e, f) were significantly
decreased throughout the study in both diet groups, and the
SOD activity was moderately increased with the HFHFr
diet compared to the control diet.
The hepatic oxidative stress was more marked than
blood oxidative stress. The liver protein carbonylation mea-
sured with the Oxyblot kit remained unchanged throughout
the study between the two experimental diets but was sig-
nificantly increased with the HFHFr diet compared to the
control diet (Fig. 7a, b). However, liver TBARS levels
were increased throughout the study but remained statisti-
cally unchanged between the two experimental diets
(Fig. 8a). Nevertheless, liver contents of SH groups and
total GSH and GssG were markedly decreased with the
HFHFr diet compared to the control diet (Fig. 8b). More-
over, the catalytic activities of the antioxidant enzymes
SOD and GPx, but not catalase, were decreased with the
HFHFr diet compared to the control diet (Fig. 8c).
Relationships between Glucose Intolerance and
Oxidative Stress Parameters
In attempt to understand the relationship between glucose
intolerance and oxidative stress, correlations between the
area under the curve (AUC) of the OGTT and oxidative
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chronic study with several end points from 4-week to
20-week diet treatment. In a recent study (Fouret et al.,
2018), we have reported that HFHFr diet, rich in fat and
fructose that imitates western diet, has been efficient in
inducing moderate overweight, increased liver and adi-
pose tissue weights, and hyperglycemia from the 8th/12th
week of diet. The results of the present study are an exten-
sion of the previous article that investigated hepatic accu-
mulation of lipotoxic metabolites as well as inflammation
and oxidative stress in these rats fed a high-fat/high-
fructose diet.
Many studies have demonstrated increased accumulation
of lipids in the liver in mice and rats receiving HF diet.
However, it is the intracellular lipotoxic metabolites (DAG
and ceramides) that are considered to be the true culprits of
the initiation and the development of glucose intolerance
and hepatic steatosis. Indeed, in addition to the marked
increase in liver triacylglycerols (TAG) and cholesterol
ester contents, our results have shown that the hepatic con-
tents of DAG species were markedly increased with the
HFHFr diet compared to the control diet and this was
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stress parameters have been sought (Fig. 9). There was a 
negative correlation between the AUC and the plasma and 
hepatic levels of sulfhydryl groups (r = −0.332, 
p = 0.0042 and r = −0.391, and p = 0.0007, respectively). 
Surprisingly, there was also a negative correlation between 
AUC and plasma and hepatic contents of isoprostanoids 
(r = −0.285, p = 0.0155 and r = −0.368, p = 0.0012, 
respectively). There was also a moderate negative correla-
tion between the AUC and the mitochondria+substrates
+ADP (r = −0.265, p = 0.0218) and a positive correlation 
with NADPH oxidase activity (r = 0.367, p = 0.0015).
Discussion
The present work was designed to determine the course-
time evolution of both inflammation and oxidative stress 
and their relation to the major MetS features, namely, glu-
cose intolerance and hepatic steatosis development, in an 
HFHFr diet-induced oxidative stress model in a large
observed at the five experimental time points of our present
study. A variety of factors are responsible for the ectopic
accumulation of DAG in the liver. These especially include
the consumption of a diet rich in fats or sugars as well as
the inability of adipose tissue to store lipids appropriately,
resulting in increased circulating unesterified fatty acids.
Indeed, hepatic DAG accumulation in both animals and
humans has been linked to hepatic insulin resistance (Finck
and Hall, 2015).
It is generally admitted that accumulation of ectopic fat
in the liver and resulting hepatic insulin resistance results
in hepatic inflammation, secondary to cytokine release
either locally by the liver or by the white adipose tissue.
(Peng et al., 2012). Some cytokines may exacerbate
NAFLD and insulin resistance, such as TNF-α or IL-6 and
others may compensate the situation, such as IL-10 and
adiponectin (Asrih and Jornayvaz, 2013). In this study,
many inflammatory cytokines we measured in blood,
liver, and adipose tissue. Our results showed that hepatic
protein abundance of IL-6 and adipose tissue gene expres-
sion of chemokine (C C motif) ligand 5 (Ccl5) was
significantly increased with the HFHFr diet compared to
the control diet. However, the other inflammation markers
(plasma TNF-α and IL-6, liver TNF-α, adipose tissue Tnf-
α, Il-6, and Mcp-1) remained unchanged. Therefore, only
limited inflammation was observed in our HFHFr rats.
Indeed, although low-grade inflammation may accompany
steatosis, frank inflammation is usually observed in the
later stages of steatosis, which, along with oxidative
stress, is responsible for the progression of steatosis to
steatohepatitis and fibrosis (Nakamura and Terauchi,
2013; Tilg and Moschen, 2010).
The critical roles of cellular ROS and oxidative stress
involved in the pathogenesis of glucose intolerance and
liver diseases have been highlighted for decades, and accu-
mulating evidence showed that a vicious cycle could be
created by oxidative stress and inflammation. Here, we
investigated the two major sources of hepatic ROS produc-
tion, namely, mitochondria and NADPH oxidase. Under
our experimental conditions, we did not observe any differ-
ence in the hepatic mitochondrial ROS production among
the studied groups; even though this does not quite exclude
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Fig. 5 Liver total isoprostanoid contents and their major classes, ng/g liver wet weight. Results were expressed as means  SD, n = 6–8 animals
per group per diet treatment duration. Hepatic isoprostanoid class A (a), isoprostanoid class B (b), isoprostanoid class C (c), isoprostanoid class D
(d), isoprostanoid class E (e), and total isoprostanoid contents (f). All the groups were tested for the effects of diet, treatment duration, and their
interaction using a two-way ANOVA. When the effects of diet or treatment duration were significant, the unpaired Student’s t-test was used to
analyze the effect of high-fat high-fructose (HFHFr) diet within each diet treatment duration point and a one-way ANOVA was applied to analyze
the effect of treatment duration for each diet followed up by a Fisher’s least significant difference test. The limit of statistical significance was set
at p < 0.05. HFHFr diet versus control diet: *p < 0.05, **p < 0.005, and ***p < 0.0005. Values with different superscript digits (1, 2, 3, and
4 for control groups) or with different superscript letters (a, b, c, d, and e for HFHFr groups) are significantly different from each other
(p < 0.05). Isoprostanoid classes: class A: radical metabolites of α-linolenic acid (18:3 n-3), class B: radical metabolites of arachidonic acid (20:4
n-6), class C: radical metabolites of adrenic acid (22:4 n-6), class D: radical metabolites of docosapentaenoic acidn-6 (22:5 n-6), and class E: radi-
cal metabolites of docosahexaenoic acid (22:6 n-3)
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the possibility that in vivo mitochondrial ROS production
may be affected. Indeed, in vitro measurement of ROS in
isolated mitochondria can skew it because it deprives mito-
chondria of their natural environment within the cell.
Higher mitochondrial ROS production with HF diets was
shown only when using palmitoyl-carnitine as substrates,
but not when using malate/glutamate/succinate as sub-
strates as in our study (Vial et al., 2011). However, another
team (Cardoso et al., 2010) has found that a high-fat diet
increased H2O2 release from mice liver mitochondria with-
out substantial alteration in respiratory rates, ADP/O ratios,
or membrane potentials of isolated liver mitochondria. It is
highly likely that there are different responses to high-fat
diets between rats and mice.
The NADPH oxidase system is another important source
of cellular ROS production and an essential component of
redox signaling mechanisms, and so it seems to play a
major role in the pathogenesis of oxidative metabolic disor-
ders (Furukawa et al., 2004; Roberts et al., 2006). Indeed,
an abnormal activation of NADPH oxidase is accompanied
by high production of superoxide anions, which is
generally related to tissue injury induced by oxidative
stress. In the present study, liver NADPH oxidase
dependent-superoxide anion production was markedly
increased with the HFHFr diet compared to the control diet
and this was at the four measured time points. However,
the protein abundance of two major NADPH oxidase com-
ponents, p22phox and p47phox, remained statistically
unchanged with the HFHFr diet compared to the control
diet. Indeed, the observed higher NADPH oxidase activity
with the HFHFr diet may result from post-translational
modifications (phosphorylation, etc.) followed by mem-
brane p47phox translocation and NADPH oxidase activation
(Brandes et al., 2014). As shown in Fig. 9f, NADPH oxi-
dase activity correlated highly positively with the glucose
intolerance test. These results suggested that NADPH
oxidase-mediated oxidative stress may contribute to glu-
cose intolerance and liver injury during high-fat diet feed-
ing. In addition and in agreement with such hypothesis, a
novel NADPH oxidase inhibitor, the GLX351322, was
reported to counteract glucose intolerance in high-fat diet-
treated C57BL/6 mice (Anvari et al., 2015). Another team
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Fig. 8 Long-established oxidative stress markers of liver. Results were expressed as means  SD, n = 6–8 animals per group per diet treatment
duration. Hepatic oxidative, thiobarbituric acid-reactive substance [TBARS] (a), antioxidative stress, SH groups, total glutathione [GSH] (b),
and superoxide dismutase [SOD], catalase and glutathione peroxidase [GPx] (c) parameters were determined. All the groups were tested for the
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the control diet, but this does not explain alone the marked
decrease in liver isoprostanoid metabolite contents as the
liver lipid level and those of PUFA were much higher in
the HFHFr rats (about +100%) compared to the control rats
(Fouret et al., 2018). When these two factors are taken
together, the liver total PUFA content decreased with the
HFHFr diets compared to the control diet. However, the
isoprostanoid metabolites/PUFA ratio remained signifi-
cantly lower with the HFHFr diet compared to the control
diet. To our knowledge, this is the first time that the iso-
prostanoid metabolites were reported in a high fat/high
fructose diet-fed rat model in both plasma and liver tissue.
In the majority of studies, only F2-isoprostane or
8-isoprostane was measured by ELISA in blood or urine
and seldom in tissues, which gave often discordant results.
These studies have reported either increased (Zhu et al.,
2008) or unchanged or (Petersson et al., 2010) even
decreased (Penumetcha et al., 2012) isoprostane levels with
HF or HF/HS diets in human or rodent models.
In line with our isoprostanoid metabolites results, the
plasma TBARS levels were also decreased whereas the
liver TBARS levels remained unchanged. However, the
other blood oxidative stress markers were only modestly
modified, whereas those measured in the liver were highly
affected with our HFHFr diet. Indeed, the protein oxidation
assessed by the oxyblot kit showed that protein carbonyla-
tion was increased under the HFHFr diet since the early
stages of the study. In addition, both liver sulfhydryl and
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Fig. 9 Correlations between glucose tolerance test and major oxidative stress markersResults were expressed as means  SD, n = 6–8 animals
per group per diet treatment duration. Correlations were performed with the Spearman method. Glucose tolerance test was negatively correlated
with some antioxidative stress parameters, namely plasma SH groups (a), hepatic SH groups (b), but also with plasma and hepatic isoprosta-
noids (c, d) and mitochondrial reactive oxygen species (ROS) production (e). Interestingly, it was positively correlated with hepatic NADPH
oxidase-dependent superoxide radical production (f). AUC: area under the curve; SH groups: sulfhydryl groups; and GSH: glutathione.
(Yang et al., 2016) has reported that oral administration of 
Salidroside prevented liver injury in the NASH model, 
through its antioxidant actions to suppress oxidative stress 
and the free radical-generating Nox2 in liver.
Several oxidative and antioxidative biomarkers have 
been proposed, including TBARS, hydroperoxides, protein 
sulfhydryl groups, and reduced and oxidized GSH as well 
as SOD, catalase, GPx to assess oxidative stress in vivo. 
However, isoprostanoids (such as 15F2t-isoprostane) origi-
nated from PUFA and formed under autooxidative condi-
tions are known to be excellent markers of lipid 
peroxidation in vivo and more generally of oxidative stress 
(Galano et al., 2017; Yin, 2008). Therefore, the strong 
point of this study is the measurement of not less than 
14 isoprostanoid metabolites in both plasma and liver tis-
sue. Surprisingly, the sum of isoprostanoid metabolites in 
both media was decreased with the HFHFr diet compared 
to the control diet. In addition, when the isoprostanoid 
metabolites were classified according to their fatty acid ori-
gin, the classes B, C, and E of plasma isoprostanoid metab-
olites were decreased, while the class A remained 
unchanged. More interestingly, four classes (A, B, C, and 
E) of liver isoprostanoid metabolites were decreased with 
the HFHFr diet compared to the control diet. Because the 
isoprostanoid metabolites are originated from specific 
PUFA, the ratio of isoprostanoid metabolites/corresponding 
PUFA was considered. Indeed, the liver PUFA percent was 
decreased by about 35% with the HFHFr diets compared to
GSH levels as well as the enzymatic activity of SOD, cata-
lase, and GPx significantly decreased with the HFHFr diet
compared to the control diet. This means that HFHFr diet
induced marked oxidative stress of proteins but the oxida-
tive stress of lipids was rather limited or inexistent.
In conclusion, in spite of long-term high-fat high-
fructose diet feeding and the high hepatic accumulation of
lipids, including DAG and ceramides, the inflammation sta-
tus as well as the ROS production and oxidative stress
markers, in particular lipid peroxidation, that is isoprosta-
noids and TBARS, remained very low if any even after
20 weeks of HFHFr diet feeding. The mitochondrial ROS
production remained unchanged while NADPH oxidase
was increased with the HFHFr diet associated with some
perturbation of hepatic protein peroxidation and its redox
status. Most of these lipid and oxidative stress changes
occurred at the same time and as early as 8 or 12 weeks of
diet treatment. This implies that low-grade oxidative stress,
which accompanied glucose intolerance and hepatic steato-
sis, may be the result, not the cause, of hepatic lipid accu-
mulation, and suggests that marked hepatic oxidative stress
should occur at the end of the steatotic stage to result in
frank insulin resistance and steatohepatitis as well as other
fatty liver diseases. These interesting findings need to be
further evaluated in other animal species as well as in
human studies.
Acknowledgements The authors wish to express their deep
acknowledgements to Guillaume Reversat and Amandine Rocher for
their technical aid in the isoprostanoid analysis. The authors wish also
to thank Marie-Agnès Chauvin for completion of Oxyblot western
blots and Charlène Couturier for qPCR analyses. The authors wish to
acknowledge the significant contribution of the kind staff of the
METAMUS DMEM facility, which belongs to Montpellier animal
facilities (RAM, BIOCAMPUS).
Authors’ Contributions Author contributions were as follows:
study design (C.F.-C., C.C.), data collection (G.F., C.V., B.B., B.J.,
A.B.-Z., J.R., J.F.L.), statistical analysis (C.C. and C.F.-C.), data inter-
pretation (C.F.-C., T.D., F.C., S.G., C.C.), manuscript preparation
(C.F.-C., S.G., C.C.), literature search (C.F.-C. and S.G., C.C.) and
funds collection (C.F.-C., S.G., C.C.).
Conflict of Interest The authors declare that they have no conflicts
of interest.
References
Anderson, E. J., Lustig, M. E., Boyle, K. E., Woodlief, T. L.,
Kane, D. A., Lin, C. T., … Neufer, P. D. (2009) Mitochondrial
H2O2 emission and cellular redox state link excess fat intake to
insulin resistance in both rodents and humans. Journal of Clinical
Investigation, 119:573–281.
Ando, K., & Fujita, T. (2009) Metabolic syndrome and oxidative
stress. Free Radical Biology and Medicine, 47:213–218.
Anvari, E., Wikstrom, P., Walum, E., & Welsh, N. (2015) The novel
NADPH oxidase 4 inhibitor GLX351322 counteracts glucose
intolerance in high-fat diet-treated C57BL/6 mice. Free Radical
Research, 49:1308–1318.
Aoun, M., Feillet-Coudray, C., Fouret, G., Chabi, B., Crouzier, D.,
Ferreri, C., … Coudray, C. (2011) Rat liver mitochondrial mem-
brane characteristics and mitochondrial functions are more pro-
foundly altered by dietary lipid quantity than by dietary lipid
quality: Effect of different nutritional lipid patterns. British Journal
of Nutrition, 107:647–659.
Asrih, M., & Jornayvaz, F. R. (2013) Inflammation as a potential link
between nonalcoholic fatty liver disease and insulin resistance.
Journal of Endocrinology, 218:R25–R36.
Barja, G. (2002) The quantitative measurement of H2O2 generation
in isolated mitochondria. Journal of Bioenergetics and Biomem-
branes, 34:227–233.
Bedard, K., & Krause, K. H. (2007) The NOX family of ROS-
generating NADPH oxidases: Physiology and pathophysiology.
Physiological Reviews, 87:245–313.
Beers, R., & Sizer, I. (1952) A spectrophotometric method for mea-
suring the breakdown of hydrogen peroxide by catalase. Journal of
Biological Chemistry, 195:133–140.
Blachnio-Zabielska, A. U., Persson, X. M., Koutsari, C.,
Zabielski, P., & Jensen, M. D. (2012) A liquid chromatography/-
tandem mass spectrometry method for measuring the in vivo incor-
poration of plasma free fatty acids into intramyocellular ceramides
in humans. Rapid Communications in Mass Spectrometry, 26:
1134–1140.
Blachnio-Zabielska, A. U., Zabielski, P., & Jensen, M. D. (2013)
Intramyocellular diacylglycerol concentrations and [U-(1)(3)C]pal-
mitate isotopic enrichment measured by LC/MS/MS. Journal of
Lipid Research, 54:1705–1711.
Bradford, M. M. (1976) A rapid and sensitive method for the quantita-
tion of microgram quantities of protein utilizing the principle of
protein-dye binding. Analytical Biochemistry, 72:248–254.
Brandes, R. P., Weissmann, N., & Schroder, K. (2014) Nox family
NADPH oxidases: Molecular mechanisms of activation. Free Radi-
cal Biololy and Medicine, 76:208–226.
Bravard, A., Bonnard, C., Durand, A., Chauvin, M. A., Favier, R.,
Vidal, H., & Rieusset, J. (2011) Inhibition of xanthine oxidase
reduces hyperglycemia-induced oxidative stress and improves mito-
chondrial alterations in skeletal muscle of diabetic mice. American
Journal of Physiology-Endocrinology and Metabolism, 300:
E581–E591.
Cardoso, A. R., Cabral-Costa, J. V., & Kowaltowski, A. J. (2010)
Effects of a high fat diet on liver mitochondria: Increased ATP-
sensitive K+ channel activity and reactive oxygen species genera-
tion. Journal of Bioenergetics and Biomembranes, 42:245–253.
Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P., & Garg, R.
(2005) Metabolic syndrome: A comprehensive perspective based
on interactions between obesity, diabetes, and inflammation. Circu-
lation, 111:1448–1454.
Dupuy, A., Le Faouder, P., Vigor, C., Oger, C., Galano, J. M.,
Dray, C., … Bertrand-Michel, J. (2016) Simultaneous quantitative
profiling of 20 isoprostanoids from omega-3 and omega-6 polyun-
saturated fatty acids by LC-MS/MS in various biological samples.
Analytica Chimica Acta, 921:46–58.
Feillet-Coudray, C., Sutra, T., Fouret, G., Ramos, J., Wrutniak-
Cabello, C., Cabello, G.,… Coudray, C. (2009) Oxidative stress in
rats fed a high-fat high-sucrose diet and preventive effect of poly-
phenols: Involvement of mitochondrial and NAD(P)H oxidase sys-
tems. Free Radical Biology and Medicine, 46:624–632.
Fernandez-Sanchez, A., Madrigal-Santillan, E., Bautista, M.,
Esquivel-Soto, J., Morales-Gonzalez, A., Esquivel-Chirino, C., …
Morales-Gonzalez, J. A. (2011) Inflammation, oxidative stress, and
obesity. International Journal of Molecular Sciences, 12:
3117–3132.
Finck, B. N., & Hall, A. M. (2015) Does diacylglycerol accumulation
in fatty liver disease cause hepatic insulin resistance? BioMed
Research International, 2015:104132.
Flohe, L., & Gunzler, W. A. (1984) Assays of glutathione peroxidase.
Methods in Enzymology, 105:114–121.
Fouret, G., Gaillet, S., Lecomte, J., Bonafos, B., Djohan, F.,
Barea, B., … Feillet-Coudray, C. (2018) 20-week follow-up of
hepatic steatosis installation and liver mitochondrial structure and
activity and their interrelation in rats fed a high-fat-high-fructose
diet. British Journal of Nutrition, 1019:368–380.
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y.,
Nakajima, Y., … Shimomura, I. (2004) Increased oxidative stress
in obesity and its impact on metabolic syndrome. Journal of Clini-
cal Investigation, 114:1752–1761.
Galano, J. M., Lee, Y. Y., Oger, C., Vigor, C., Vercauteren, J.,
Durand, T., … Lee, J. C. (2017) Isoprostanes, neuroprostanes and
phytoprostanes: An overview of 25years of research in chemistry
and biology. Progress in Lipid Research, 68:83–108.
Gerner, R. R., Wieser, V., Moschen, A. R., & Tilg, H. (2013) Meta-
bolic inflammation: Role of cytokines in the crosstalk between adi-
pose tissue and liver. Canadian Journal of Physiology and
Pharmacology, 91:867–872.
Griffith, O. W. (1980) Determination of glutathione and glutathione
disulfide using glutathione reductase and 2-vinylpyridine. Analyti-
cal Biochemistry, 106:207–212.
Jocelyn, P. C. (1987) Spectrophotometric assay of thiols. Methods in
Enzymology, 143:44–67.
Johnson, R. J., Stenvinkel, P., Martin, S. L., Jani, A., Sanchez-
Lozada, L. G., Hill, J. O., & Lanaspa, M. A. (2013) Redefining
metabolic syndrome as a fat storage condition based on studies of
comparative physiology. Obesity (Silver Spring), 21:659–664.
Kawano, Y., & Cohen, D. E. (2013) Mechanisms of hepatic triglycer-
ide accumulation in non-alcoholic fatty liver disease. Journal of
Gastroenterology, 48:434–441.
Li, S., Hong, M., Tan, H. Y., Wang, N., & Feng, Y. (2016) Insights
into the role and interdependence of oxidative stress and inflamma-
tion in liver diseases. Oxidative Medicine and Cellular Longevity,
2016:4234061.
Mantena, S. K., King, A. L., Andringa, K. K., Eccleston, H. B., &
Bailey, S. M. (2008) Mitochondrial dysfunction and oxidative
stress in the pathogenesis of alcohol- and obesity-induced fatty liver
diseases. Free Radical in Biology and Medicine, 44:1259–1272.
Marklund, S. (1976) Spectrophotometric study of spontaneous dispro-
portionation of superoxide anion radical and sensitive direct assay
for superoxide dismutase. Journal of Biological Chemistry, 251:
7504–7507.
Nakamura, A., & Terauchi, Y. (2013) Lessons from mouse models of
high-fat diet-induced NAFLD. International Journal of Molecular
Sciences, 14:21240–21257.
Paik, Y. H., & Brenner, D. A. (2011) NADPH oxidase mediated oxi-
dative stress in hepatic fibrogenesis. Korean Journal of Hepatol-
ogy, 17:251–257.
Peng, Y., Rideout, D., Rakita, S., Lee, J., & Murr, M. (2012) Diet-
induced obesity associated with steatosis, oxidative stress, and
inflammation in liver. Surgery for Obesity and Related Diseases, 8:
73–81.
Penumetcha, M., Song, M., Merchant, N., & Parthasarathy, S. (2012)
Pretreatment with n-6 PUFA protects against subsequent high fat
diet induced atherosclerosis-potential role of oxidative stress-
induced antioxidant defense. Atherosclerosis, 220:53–58.
Perry, R. J., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2014)
The role of hepatic lipids in hepatic insulin resistance and type
2 diabetes. Nature, 510:84–91.
Petersen, M. C., & Shulman, G. I. (2017) Roles of diacylglycerols
and ceramides in hepatic insulin resistance. Trends in Pharmaco-
logical Sciences, 38:649–665.
Petersson, H., Riserus, U., McMonagle, J., Gulseth, H. L.,
Tierney, A. C., Morange, S., … Basu, S. (2010) Effects of dietary
fat modification on oxidative stress and inflammatory markers in
the LIPGENE study. British Journal of Nutrition, 104:1357–1362.
Renaud, H. J., Cui, J. Y., Lu, H., & Klaassen, C. D. (2014) Effect of
diet on expression of genes involved in lipid metabolism, oxidative
stress, and inflammation in mouse liver-insights into mechanisms
of hepatic steatosis. PLoS One, 9:e88584.
Roberts, C. K., Barnard, R. J., Sindhu, R. K., Jurczak, M.,
Ehdaie, A., & Vaziri, N. D. (2006) Oxidative stress and dysregula-
tion of NAD(P)H oxidase and antioxidant enzymes in diet-induced
metabolic syndrome. Metabolism, 55:928–934.
Sunderman Jr., F. W., Marzouk, A., Hopfer, S. M., Zaharia, O., &
Reid, M. C. (1985) Increased lipid peroxidation in tissues of nickel
chloride-treated rats. Annals of Clinical & Laboratory Science, 15:
229–236.
Tilg, H., & Moschen, A. R. (2010) Evolution of inflammation in non-
alcoholic fatty liver disease: The multiple parallel hits hypothesis.
Hepatology, 52:1836–1846.
Tordjman, J., Guerre-Millo, M., & Clement, K. (2008) Adipose tissue
inflammation and liver pathology in human obesity. Diabetes &
Metabolism, 34:658–663.
Ucar, F., Sezer, S., Erdogan, S., Akyol, S., Armutcu, F., & Akyol, O.
(2013) The relationship between oxidative stress and nonalcoholic
fatty liver disease: Its effects on the development of nonalcoholic
steatohepatitis. Redox Report, 18:127–133.
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., &
Telser, J. (2007) Free radicals and antioxidants in normal physio-
logical functions and human disease. International Journal of Bio-
chemistry & Cell Biology, 39:44–84.
Vial, G., Dubouchaud, H., Couturier, K., Cottet-Rousselle, C.,
Taleux, N., Athias, A.,… Leverve, X. M. (2011) Effects of a high-
fat diet on energy metabolism and ROS production in rat liver.
Journal of Hepatology, 54:348–356.
Witko-Sarsat, V., Friedlander, M., Nguyen Khoa, T., Capeillere-
Blandin, C., Nguyen, A. T., Canteloup, S., … Descamps-
Latscha, B. (1998) Advanced oxidation protein products as novel
mediators of inflammation and monocyte activation in chronic renal
failure. Journal of Immunology, 161:2524–2532.
Yagi, K. (1984) Assay for blood plasma or serum. Methods in Enzy-
mology, 105:328–331.
Yang, Z. R., Wang, H. F., Zuo, T. C., Guan, L. L., & Dai, N. (2016)
Salidroside alleviates oxidative stress in the liver with non-
alcoholic steatohepatitis in rats. BMC Pharmacology and Toxicol-
ogy, 17:16.
Yin, H. (2008) New techniques to detect oxidative stress markers:
Mass spectrometry-based methods to detect isoprostanes as the gold
standard for oxidative stress in vivo. BioFactors, 34:109–124.
Zhu, M. J., Sun, L. J., Liu, Y. Q., Feng, Y. L., Tong, H. T.,
Hu, Y. H., & Zhao, Z. (2008) Blood F2-isoprostanes are signifi-
cantly associated with abnormalities of lipid status in rats with stea-
tosis. World Journal of Gastroenterology, 14:4677–4683.
Zivkovic, A. M., German, J. B., & Sanyal, A. J. (2007) Comparative
review of diets for the metabolic syndrome: Implications for nonal-
coholic fatty liver disease. American Journal of Clinical Nutrition,
86:285–300.
